Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 AUD | +6.25% | -5.56% | -51.43% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
Evolution of the average Target Price on Chimeric Therapeutics Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CHM Stock
- Consensus Chimeric Therapeutics Limited